贝达药业：在肺癌治疗领域，CFT8919和MCLA-129项目目前正在全力推进中

Core Insights - The company has established a robust cycle of "R&D-commercialization-reinvestment," leading to steady revenue growth and cash flow reserves that meet operational needs and support the orderly advancement of its R&D pipeline [1] - The company employs a dynamic project evaluation mechanism to select projects with higher clinical value and market potential, optimizing resource allocation and pipeline layout [1] - In the field of lung cancer treatment, the company is actively advancing the CFT8919 and MCLA-129 projects [1] Group 1 - The company has achieved stable revenue increments and cash flow reserves, ensuring operational needs are met [1] - The company focuses on R&D directions with greater clinical value and market potential through a mature project evaluation mechanism [1] - The CFT8919 and MCLA-129 projects are currently being prioritized in lung cancer treatment [1] Group 2 - An investor raised concerns about the company's BPI-361175, a fourth-generation EGFR-TKI, questioning why the company has not accelerated its development despite being ahead of competitors [3] - The investor speculated whether the company is facing funding constraints that could hinder further research on the fourth-generation drug [3] - There is a concern that the company might fall behind in fourth-generation drug development, similar to its experience with third-generation drugs [3]